TAZIDIME Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tazidime, and what generic alternatives are available?
Tazidime is a drug marketed by Lilly and is included in two NDAs.
The generic ingredient in TAZIDIME is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tazidime
A generic version of TAZIDIME was approved as ceftazidime by ACS DOBFAR on November 20th, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TAZIDIME?
- What are the global sales for TAZIDIME?
- What is Average Wholesale Price for TAZIDIME?
Summary for TAZIDIME
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Patent Applications: | 8,286 |
| DailyMed Link: | TAZIDIME at DailyMed |
US Patents and Regulatory Information for TAZIDIME
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | TAZIDIME | ceftazidime | INJECTABLE;INJECTION | 062655-001 | Nov 20, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | TAZIDIME IN PLASTIC CONTAINER | ceftazidime | INJECTABLE;INJECTION | 062739-002 | Jul 10, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | TAZIDIME | ceftazidime | INJECTABLE;INJECTION | 062655-002 | Nov 20, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
